Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives
- 15 August 1995
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 92 (4) , 825-834
- https://doi.org/10.1161/01.cir.92.4.825
Abstract
Background Angiotensin-converting enzyme (ACE) inhibitors do not decrease plasma angiotensin (Ang) II levels 24 hours after drug intake to the same extent as at peak. This intermittent partial “escape” is explained either by a renin-mediated reactive rise in plasma Ang I or by non–ACE-dependent Ang II generation. We therefore tested the hypothesis that a combination of ACE inhibition and Ang II blockade may have additive biological and hemodynamic effects. Methods and Results In a single-dose, double-blind, randomized, four-way, crossover study, an Ang II antagonist (losartan 50 mg), an ACE inhibitor (captopril 50 mg), their combination, and matched placebos were orally administered to 12 normotensive male volunteers maintained in mild sodium depletion. When captopril 50 mg and losartan 50 mg were given alone, the magnitude of their effects on blood pressure, plasma active renin, Ang I, and aldosterone was similar, whereas the kinetics of their effects were different, reflecting differences in drug pharmacokinetics. The losartan-captopril combination completely suppressed the rise in plasma Ang II induced by losartan 2 hours after drug intake (3.3±3.6 pg/mL versus 20.3±19.1 pg/mL, respectively, P <.05). Six hours after drug intake, the losartan-captopril combination induced a significantly greater decrease in mean blood pressure than that produced by either losartan or captopril alone (73±7 mm Hg versus 79±8 mm Hg versus 81±7 mm Hg, respectively, P <.05). The maximum placebo-subtracted falls in mean blood pressure for the losartan-captopril combination, captopril 50 mg, and losartan 50 mg were 14±5 mm Hg, 10±3 mm Hg, and 9±6 mm Hg, respectively (F2.22=3.45, P <.05). The duration of the mean blood pressure fall was not prolonged by the combination. After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404±2961 pg · h · mL −1 versus 3105±1461 pg · h · mL −1 versus 2092±867 pg · h · mL −1 , respectively, P <.05). The combination had no additive effects on plasma aldosterone decrease when compared with either losartan or captopril alone (58±17% versus 51±20% versus 53±21%, respectively, NS). Conclusions The combined administration of a standard single oral dose of an ACE inhibitor and an Ang II antagonist to mildly sodium-depleted normal subjects (1) had a major additive effect on plasma renin rise, (2) induced an additional mean blood pressure reduction, and (3) had no additive effect on plasma aldosterone fall.Keywords
This publication has 34 references indexed in Scilit:
- Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatmentJournal Of Hypertension, 1992
- Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril.Hypertension, 1992
- Renin release regulation during acute renin inhibition in normal volunteers.Hypertension, 1991
- Determinants of angiotensin II generation during converting enzyme inhibition.Hypertension, 1990
- Reactive Hyperreninemia Is a Major Determinant of Plasma Angiotensin II During ACE InhibitionJournal of Cardiovascular Pharmacology, 1990
- Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal humans. Studies using a direct immunoradiometric assay.Journal of Clinical Investigation, 1989
- In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and IILife Sciences, 1988
- Measurement of Active Renin by the 4G1 Anti-Human Renin Monoclonal AntibodyClinical and Experimental Hypertension. Part A: Theory and Practice, 1987
- True versus immunoreactive angiotensin II in human plasma.Hypertension, 1985
- Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in ManNew England Journal of Medicine, 1978